EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, United Therapeutics's Enterprise Value is $8,725 Mil.
United Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $748 Mil. Therefore, United Therapeutics's EV-to-FCF for today is 11.67.
The historical rank and industry rank for United Therapeutics's EV-to-FCF or its related term are showing as below:
UTHR'
s EV-to-FCF Range Over the Past 10 Years
Min: -15.99 Med: 11.69 Max: 29.37
Current: 11.67
During the past 13 years, the highest EV-to-FCF of United Therapeutics was 29.37. The lowest was -15.99. And the median was 11.69.
UTHR's EV-to-FCF is ranked worse than 58.87% of 389
companies
in the Biotechnology industry
Industry Median: 4.27
vs UTHR: 11.67
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), United Therapeutics's stock price is $238.10.
United Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $19.840. Therefore, United Therapeutics's PE Ratio for today is 12.00.
United Therapeutics EV-to-FCF Historical Data
The historical data trend for United Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, United Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics EV-to-FCF Distribution
For the Biotechnology industry and Healthcare sector, United Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where United Therapeutics's EV-to-FCF falls into.
United Therapeutics EV-to-FCF Calculation
United Therapeutics's EV-to-FCF for today is calculated as:
United Therapeutics's current Enterprise Value is $8,725 Mil.
United Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $748 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (NAS:UTHR) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
United Therapeutics's PE Ratio for today is calculated as:
United Therapeutics's share price for today is $238.10.
United Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.840.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
United Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of United Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
United Therapeutics (United Therapeutics) Business Description
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
UTHR has been successfully added to your 